



SYIS – STUDENT MEET MENTOR

Mark Ferguson

Mark Ferguson is the Co-founder (with Dr Sharon O'Kane) and CEO of Renovo a Biotechnology Company spun out of the University of Manchester, which is developing novel pharmaceutical therapies to prevent scarring or accelerate healing following wounding (www.renovo.com). Following two rounds of private venture capital funding (totalling £32M) Renovo successfully completed an IPO on the Main list of the London Stock Exchange in April 2006, raising £67.5M. Renovo partnered its lead drug, Juvista for scar reduction, with Shire in a \$825M plus royalties deal retaining all EU rights, where it intends to commercialise itself. Renovo has three drugs in the clinic: Juvista in PhIII, with 8 clinically and statistically significant PII efficacy trials, Juvidex, Adaprev and Prevascar in PII, and over a dozen preclinical candidates. Since the age of 28, Mark Ferguson has been Professor in the School of Biological Sciences at the University of Manchester, where he has held a number of administrative posts including Head of Department and Dean.